Literature DB >> 4006363

Effect of cigarette smoking on mexiletine kinetics.

O Grech-Bélanger, M Gilbert, J Turgeon, P P LeBlanc.   

Abstract

The effect of cigarette smoking on the kinetics of a single, 200 mg, oral dose of the antiarrhythmic drug mexiletine was investigated in healthy subjects. Cigarette smoking had no effect on absorption or distribution of the drug, but it significantly reduced the elimination t1/2 from 11.1 +/- 3.4 to 7.2 +/- 1.8 hours; the effect on clearance was less significant. Determination of the urinary concentrations of the three major metabolites of mexiletine (mexiletine glucuronide conjugate, hydroxymethylmexiletine, and p-hydroxymexiletine) indicated that cigarette smoking selectively induced conjugation of mexiletine with glucuronic acid as well as aliphatic hydroxylation to yield hydroxymethylmexiletine, but that it had no effect on the formation of p-hydroxymexiletine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4006363     DOI: 10.1038/clpt.1985.103

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

1.  Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2.

Authors:  K Kobayashi; M Nakajima; K Chiba; T Yamamoto; M Tani; T Ishizaki; Y Kuroiwa
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

Review 2.  Clinical pharmacokinetics of mexiletine.

Authors:  L Labbé; J Turgeon
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

Review 3.  Mexiletine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.

Authors:  J P Monk; R N Brogden
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

Review 4.  Drug interactions with tobacco smoking. An update.

Authors:  S Zevin; N L Benowitz
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

5.  The effect of tocainide on theophylline metabolism.

Authors:  C M Loi; X Wei; B M Parker; M R Korrapati; R E Vestal
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

6.  Impact of CYP2D6*10 on mexiletine pharmacokinetics in healthy adult volunteers.

Authors:  Masahiro Otani; Tsuyoshi Fukuda; Masakazu Naohara; Hiromi Maune; Chiaki Senda; Isamu Yamamoto; Junichi Azuma
Journal:  Eur J Clin Pharmacol       Date:  2003-08-23       Impact factor: 2.953

7.  The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.

Authors:  F Broly; N Vandamme; C Libersa; M Lhermitte
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

Review 8.  Mexiletine. A review of its therapeutic use in painful diabetic neuropathy.

Authors:  B Jarvis; A J Coukell
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

9.  Involvement of CYP1A2 in mexiletine metabolism.

Authors:  M Nakajima; K Kobayashi; N Shimada; S Tokudome; T Yamamoto; Y Kuroiwa
Journal:  Br J Clin Pharmacol       Date:  1998-07       Impact factor: 4.335

10.  Stereoselective disposition of mexiletine in man.

Authors:  O Grech-Belanger; J Turgeon; M Gilbert
Journal:  Br J Clin Pharmacol       Date:  1986-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.